Physician profile

Gretchen E Farmer

Internal Medicine · Union, MO

NPI 1720283450

$6,293.25

in general payments reported to CMS, 2019-2025

42 companies · $1,044 in 2025

The $1,044 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$3,320.69
Education$77.08

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $1,271.04 2021-2025
Novo Nordisk INC $966.10 2019-2025 Rybelsus, Ozempic, Wegovy
Astrazeneca Pharmaceuticals Lp $437.81 2019-2025 Breztri, Farxiga, Airsupra
Pfizer INC. $335.88 2019-2025
Boehringer Ingelheim Pharmaceuticals, INC. $295.05 2019-2025 Jardiance, Tradjenta, Synjardy
Supernus Pharmaceuticals, INC. $284.12 2019-2024 Qelbree, Qelbree
Lilly USA, LLC $282.68 2019-2025 Mounjaro, Jardiance, Zepbound
Otsuka America Pharmaceutical, INC. $247.49 2022-2025 Rexulti
Glaxosmithkline, LLC. $225.20 2020-2025 Trelegy Ellipta, Arexvy, Shingrix
Amgen INC. $214.01 2019-2025 Prolia, Evenity, Repatha
Tris Pharma INC $199.98 2019-2025 Dyanavel Xr
Dexcom, INC. $129.21 2021-2025 Dexcom G6 Transmitter
Exact Sciences Corporation $122.98 2023-2025 Cologuard Collection Kit, The Cologuard Plus Collection Kit
Ironshore Pharmaceuticals INC. $109.72 2019-2024 Jornay Pm
Collegium Pharmaceutical, INC. $93.51 2025 Jornay Pm
Show all 42 companies
CompanyGeneral paymentsYearsTop products
Lundbeck LLC $77.08 2025 Rexulti
Sanofi-Aventis U.S. LLC $74.98 2019-2025
Phathom Pharmaceuticals, INC. $71.89 2025 Voquezna
Bayer Healthcare Pharmaceuticals INC. $70.68 2021-2023
Merck Sharp & Dohme LLC $65.14 2019-2021
Corium, LLC $65.08 2022-2023 Azstarys
Takeda Pharmaceuticals U.S.A., INC. $59.24 2019-2024 Trintellix
Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) $58.89 2025 Caplyta
Allergan, INC. $57.43 2020
Biohaven Pharmaceuticals, INC. $50.98 2020-2021
Amarin Pharma, INC. $43.11 2020-2021
Alk-Abello, INC $40.12 2025 Neffy
Axsome Therapeutics, INC. $37.21 2023-2024 Auvelity
Cranial Technologies, INC $36.40 2021-2023 Doc Band
Genentech USA, INC. $30.38 2019
Janssen Pharmaceuticals, INC $30.19 2019-2021
Sanofi Pasteur INC. $29.87 2019-2022
Sumitomo Pharma America, INC. $22.08 2023 Gemtesa
Ge Healthcare $21.75 2019
Viatris Specialty LLC $21.24 2025 Yupelri
Sunovion Pharmaceuticals INC. $18.55 2019
Astellas Pharma US INC $18.54 2020
Noven Therapeutics, LLC $17.62 2025 Xelstrym
Novartis Pharmaceuticals Corporation $16.76 2019
Neos Therapeutics, Lp $16.17 2024 Adzenys Xr-Odt
Abbott Laboratories $14.47 2022
Acerus Pharmaceuticals Corporation $12.62 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Gretchen E Farmer

$6,293.25

in general payments reported 2019-2025

Years
2019-2025
Top company
Abbvie INC.
Context
The $1,044 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).

https://glasscript.com/doctor/213902/gretchen-e-farmer

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.